Geographical Expansion Boehringer Ingelheim recently expanded its facilities to Georgia, indicating potential sales opportunities in the Southeast region of the U.S. where the company can explore new markets and partnerships.
Collaborative Projects Through collaborations with organizations like C4tbh, World Health Organisation, and NCD Alliance, Boehringer Ingelheim is engaging in various projects that could lead to opportunities for introducing new products and technologies to diverse healthcare sectors globally.
Precision Medicine Focus Boehringer Ingelheim's focus on developing novel precision cancer treatments and therapeutics for schizophrenia showcases a commitment to cutting-edge research, offering potential sales avenues in the precision medicine market segment.
Strategic Partnerships The partnership with Circle Pharma demonstrates a strategic move by Boehringer Ingelheim to collaborate on developing a first-in-class cyclin inhibitor for cancer treatment, indicating opportunities for future product sales and advancements in oncology therapeutics.
Investment in Digital Health Boehringer Ingelheim's collaboration with Dartmouth's Center for Technology and Behavioral Health to develop Digital Health tools underlines a focus on technology-driven healthcare solutions, suggesting potential sales growth in the digital health and telemedicine market segments.
96K
$1B
93K$1B
54K$1B
73K$1B
103K$1B
102K$1B
78K$1B
87K$1B
93K$1B
36K$1B
15K$1BBoehringer Ingelheim uses 8 technology products and services including Adobe Target, NumPy, SAS/STAT, and more. Explore Boehringer Ingelheim's tech stack below.
| Boehringer Ingelheim Email Formats | Percentage |
| First.Last@boehringer-ingelheim.com | 96% |
| Last.First@boehringer-ingelheim.com | 2% |
| First.Middle@boehringer-ingelheim.com | 1% |
| FirstLast@boehringer-ingelheim.com | 1% |
| FLast@rdg.boehringer-ingelheim.com | 59% |
| Last@rdg.boehringer-ingelheim.com | 32% |
| Last.First@rdg.boehringer-ingelheim.com | 2% |
| First.Last@rdg.boehringer-ingelheim.com | 2% |
| First_L@rdg.boehringer-ingelheim.com | 1% |
| Last_First@rdg.boehringer-ingelheim.com | 1% |
| LastFir@rdg.boehringer-ingelheim.com | 1% |
| L.First@rdg.boehringer-ingelheim.com | 1% |
| FirstLas@rdg.boehringer-ingelheim.com | 1% |
| FLast@bi-vetmedica.com | 79% |
| First.Last@bi-vetmedica.com | 11% |
| FirstL@bi-vetmedica.com | 6% |
| LF@bi-vetmedica.com | 1% |
| Last_F@bi-vetmedica.com | 1% |
| Last.First@bi-vetmedica.com | 1% |
| First-L@bi-vetmedica.com | 1% |
Pharmaceutical ManufacturingGermany10001+ Employees
Our people are our strength. And, together with over 53,000 colleagues, we're creating the next breakthrough in the world of health and innovation for both humans and animals. Are you ready to join us? #LifeForward
Company Overview
Media & News
Funding & FinancialsBoehringer Ingelheim's revenue is in the range of $1B
Funding & FinancialsBoehringer Ingelheim's revenue is in the range of $1B
1-888-653-2347 
support@leadiq.com